This study looks at how a medicine called dexrazoxane hydrochloride affects certain substances in the blood called biomarkers, which are linked to heart problems like cardiomyopathy and heart failure after cancer treatment. Dexrazoxane hydrochloride (DRZ) is a drug that might help protect the heart. The study will compare cancer patients who took DRZ with those who did not, looking at their heart health markers.

Patients will undergo tests, including a physical exam, echocardiogram (an ultrasound test for the heart), blood tests, and a 6-minute walk test. They will also answer questionnaires about quality of life, family history, and physical activity.

• Participants must have had cancer treatment and be in remission or have relapsed.
• The study is open for those who have medical records available and meet the criteria.
• Patients will need to sign a consent form to participate.

This study will help doctors understand if DRZ can reduce heart problems in cancer survivors and improve their long-term health.